anaptysbio - ANAB
ANAB
Close Chg Chg %
15.00 -0.45 -3.00%
Closed Market
14.55
-0.45 (3.00%)
Volume: 1.59M
Last Updated:
Dec 20, 2024, 4:00 PM EDT
Company Overview: anaptysbio - ANAB
ANAB Key Data
| Open $14.82 | Day Range 14.21 - 15.29 |
| 52 Week Range 14.20 - 41.31 | Market Cap $456.43M |
| Shares Outstanding 30.43M | Public Float 26.01M |
| Beta -0.11 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$6.07 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 788.14K |
ANAB Performance
| 1 Week | -6.67% | ||
| 1 Month | -34.67% | ||
| 3 Months | -62.19% | ||
| 1 Year | -29.85% | ||
| 5 Years | -8.43% |
ANAB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About anaptysbio - ANAB
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
ANAB At a Glance
AnaptysBio, Inc.
10770 Wateridge Circle
San Diego, California 92121-5801
| Phone | 1-858-362-6295 | Revenue | 17.16M | |
| Industry | Biotechnology | Net Income | -163,619,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 66.783% | |
| Fiscal Year-end | 12 / 2024 | Employees | 117 | |
| View SEC Filings |
ANAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 33.614 |
| Price to Book Ratio | 6.466 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.325 |
| Enterprise Value to Sales | 29.984 |
| Total Debt to Enterprise Value | 0.639 |
ANAB Efficiency
| Revenue/Employee | 146,641.026 |
| Income Per Employee | -1,398,452.991 |
| Receivables Turnover | 2.504 |
| Total Asset Turnover | 0.032 |
ANAB Liquidity
| Current Ratio | 10.866 |
| Quick Ratio | 10.866 |
| Cash Ratio | 10.44 |
ANAB Profitability
| Gross Margin | 86.151 |
| Operating Margin | -915.498 |
| Pretax Margin | -953.681 |
| Net Margin | -953.657 |
| Return on Assets | -30.791 |
| Return on Equity | -93.442 |
| Return on Total Capital | -39.263 |
| Return on Invested Capital | -32.748 |
ANAB Capital Structure
| Total Debt to Total Equity | 372.996 |
| Total Debt to Total Capital | 78.858 |
| Total Debt to Total Assets | 72.641 |
| Long-Term Debt to Equity | 370.979 |
| Long-Term Debt to Total Capital | 78.432 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Anaptysbio - ANAB
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 75.00M | 63.17M | 10.29M | 17.16M | |
Sales Growth
| +837.50% | -15.77% | -83.72% | +66.78% | |
Cost of Goods Sold (COGS) incl D&A
| - | - | 2.33M | 2.38M | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 559.00K | 2.09M | 2.33M | 2.38M | |
Depreciation
| - | 559.00K | 2.09M | 2.33M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | +1.76% | - |
Gross Income
| - | - | 7.95M | 14.78M | - |
Gross Income Growth
| - | - | - | +85.88% | - |
Gross Profit Margin
| - | - | +77.30% | +86.15% | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 98.32M | 117.90M | 123.11M | 171.85M | |
Research & Development
| 79.47M | 96.41M | 86.46M | 131.63M | |
Other SG&A
| 18.85M | 21.49M | 36.64M | 40.22M | |
SGA Growth
| -14.44% | +19.91% | +4.42% | +39.60% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (100.00K) | (100.00K) | 7.34M | |
EBIT after Unusual Expense
| (23.78M) | (56.71M) | (115.15M) | (164.41M) | |
Non Operating Income/Expense
| 3.85M | (1.08M) | 7.56M | 18.87M | |
Non-Operating Interest Income
| 3.96M | 431.00K | 7.55M | 18.87M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 21.11M | 18.08M | - |
Interest Expense Growth
| - | - | -100.00% | -14.33% | - |
Gross Interest Expense
| - | - | 21.11M | 18.08M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (19.93M) | (57.80M) | (128.70M) | (163.62M) | |
Pretax Income Growth
| +79.56% | -189.98% | -122.68% | -27.14% | |
Pretax Margin
| -26.57% | -91.49% | -1,251.09% | -953.68% | |
Income Tax
| - | - | 24.00K | (4.00K) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (19.93M) | (57.80M) | (128.72M) | (163.62M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (19.93M) | (57.80M) | (128.72M) | (163.62M) | |
Net Income Growth
| +79.52% | -189.98% | -122.72% | -27.11% | |
Net Margin Growth
| -26.57% | -91.49% | -1,251.33% | -953.66% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (19.93M) | (57.80M) | (128.72M) | (163.62M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (19.93M) | (57.80M) | (128.72M) | (163.62M) | |
EPS (Basic)
| -0.73 | -2.107 | -4.5704 | -6.0771 | |
EPS (Basic) Growth
| +79.71% | -188.63% | -116.92% | -32.97% | |
Basic Shares Outstanding
| 27.30M | 27.43M | 28.16M | 26.92M | |
EPS (Diluted)
| -0.73 | -2.107 | -4.5704 | -6.0771 | |
EPS (Diluted) Growth
| +79.71% | -188.63% | -116.92% | -32.97% | |
Diluted Shares Outstanding
| 27.30M | 27.43M | 28.16M | 26.92M | |
EBITDA
| (23.32M) | (54.72M) | (112.82M) | (154.70M) | |
EBITDA Growth
| +78.19% | -134.67% | -106.16% | -37.12% | |
EBITDA Margin
| -31.09% | -86.62% | -1,096.71% | -901.65% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 36.90 | |
| Number of Ratings | 11 | Current Quarters Estimate | -1.619 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -6.084 | |
| Last Quarter’s Earnings | -1.14 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -6.08 | Next Fiscal Year Estimate | -5.364 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 9 | 11 | 11 |
| Mean Estimate | -1.62 | -1.37 | -6.08 | -5.36 |
| High Estimates | -1.25 | -0.96 | -5.70 | -3.70 |
| Low Estimate | -2.04 | -1.77 | -6.53 | -7.36 |
| Coefficient of Variance | -13.24 | -21.73 | -3.77 | -22.26 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 9 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Buy |
SEC Filings for Anaptysbio - ANAB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Anaptysbio - ANAB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 25, 2024 | Dennis M. Mulroy CHIEF FINANCIAL OFFICER | 20,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 25, 2024 | Eric J. Loumeau CHIEF LEGAL OFFICER | 20,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 25, 2024 | Daniel R. Faga CEO; Director | 160,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 25, 2024 | Paul F. Lizzul Chief Medical Officer | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 18, 2024 | Hollings Chase Renton Director | 11,950 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.93 per share | 82,813.50 |
| Jul 18, 2024 | Hollings Chase Renton Director | 4,847 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.5 per share | 147,833.50 |
| Jul 18, 2024 | Hollings Chase Renton Director | 1,950 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.98 per share | 60,411.00 |
| Jul 18, 2024 | Hollings Chase Renton Director | 30,925 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 25, 2024 | Dennis M. Fenton Director | 1,950 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.17 per share | 45,181.50 |
| Jun 19, 2024 | Rita I. Jain Director | 4,534 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | J. Anthony Ware Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | J. Anthony Ware Director | 7,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | John A. Orwin Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | John A. Orwin Director | 2,035 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | John P. Schmid Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | John P. Schmid Director | 3,900 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | Magda Marquet Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | Magda Marquet Director | 3,900 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | Rita I. Jain Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 19, 2024 | Rita I. Jain Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |